Table 2.
Characteristics | All samples N Percentage (%) |
Training N Percentage (%) |
Validation N Percentage (%) |
P | |||
---|---|---|---|---|---|---|---|
Age(years) | |||||||
<65 | 773 | 44.20% | 523 | 44.06% | 250 | 44.48% | 0.8678 |
>65 | 976 | 55.80% | 664 | 55.94% | 312 | 55.52% | |
Sex | |||||||
female | 476 | 27.22% | 337 | 28.39% | 139 | 24.73% | 0.1085 |
male | 1273 | 72.78% | 850 | 71.61% | 423 | 75.27% | |
Race | |||||||
American Indian/Alaska Native | 16 | 0.91% | 10 | 0.84% | 6 | 1.07% | 0.9427 |
Asian/Pacific Islander | 194 | 11.09% | 134 | 11.29% | 60 | 10.68% | |
Black | 281 | 16.07% | 189 | 15.92% | 92 | 16.37% | |
White | 1258 | 71.93% | 854 | 71.95% | 404 | 71.89% | |
Primary Site | |||||||
Cardia | 741 | 42.37% | 507 | 42.71% | 234 | 41.64% | 0.9731 |
Pylorus | 88 | 5.03% | 58 | 4.89% | 30 | 5.34% | |
Body | 153 | 8.75% | 107 | 9.01% | 46 | 8.19% | |
Antrum | 265 | 15.15% | 182 | 15.33% | 83 | 14.77% | |
Fundus | 26 | 1.49% | 17 | 1.43% | 9 | 1.60% | |
Lesser curve | 104 | 5.95% | 70 | 5.90% | 34 | 6.05% | |
Greater curve | 60 | 3.43% | 42 | 3.54% | 18 | 3.20% | |
Other | 312 | 17.84% | 204 | 17.19% | 108 | 19.22% | |
Histologic type | |||||||
Adenocarcinoma | 1452 | 83.02% | 983 | 82.81% | 469 | 83.45% | 0.9448 |
Signet ring cell | 127 | 7.26% | 87 | 7.33% | 40 | 7.12% | |
Special type | 170 | 9.72% | 117 | 9.86% | 53 | 9.43% | |
Grade | |||||||
I | 43 | 2.46% | 31 | 2.61% | 12 | 2.14% | 0.0936 |
II | 553 | 31.62% | 374 | 31.51% | 179 | 31.85% | |
III | 1113 | 63.64% | 762 | 64.20% | 351 | 62.46% | |
IV | 40 | 2.29% | 20 | 1.68% | 20 | 3.56% | |
T Stage | |||||||
T0 | 2 | 0.11% | 1 | 0.08% | 1 | 0.18% | 0.9488 |
T1 | 688 | 39.34% | 472 | 39.76% | 216 | 38.43% | |
T2 | 99 | 5.66% | 65 | 5.48% | 34 | 6.05% | |
T3 | 418 | 23.90% | 283 | 23.84% | 135 | 24.02% | |
T4 | 542 | 30.99% | 366 | 30.83% | 176 | 31.32% | |
N Stage | |||||||
N0 | 674 | 38.54% | 459 | 38.67% | 215 | 38.26% | 0.9483 |
N1 | 788 | 45.05% | 537 | 45.24% | 251 | 44.66% | |
N2 | 144 | 8.23% | 97 | 8.17% | 47 | 8.36% | |
N3 | 143 | 8.18% | 94 | 7.92% | 49 | 8.72% | |
Radiotherapy | |||||||
Yes | 325 | 18.58% | 215 | 18.11% | 110 | 19.57% | 0.4635 |
No | 1424 | 81.42% | 972 | 81.89% | 452 | 80.43% | |
Chemotherapy | |||||||
Yes | 1061 | 60.66% | 727 | 61.25% | 334 | 59.43% | 0.4678 |
No | 688 | 39.34% | 460 | 38.75% | 228 | 40.57% | |
Surgery | |||||||
Yes | 240 | 13.72% | 161 | 13.56% | 79 | 14.06% | 0.7795 |
No | 1509 | 86.28% | 1026 | 86.44% | 483 | 85.94% | |
Bone Metastasis | |||||||
Yes | 157 | 8.98% | 103 | 8.68% | 54 | 9.61% | 0.5246 |
No | 1592 | 91.02% | 1084 | 91.32% | 508 | 90.39% | |
Brain Metastasis | |||||||
Yes | 24 | 1.37% | 13 | 1.10% | 11 | 1.96% | 0.1478 |
No | 1725 | 98.63% | 1174 | 98.90% | 551 | 98.04% | |
Lung Metastasis | |||||||
Yes | 297 | 16.98% | 199 | 16.76% | 98 | 17.44% | 0.7264 |
No | 1452 | 83.02% | 988 | 83.24% | 464 | 82.56% | |
Marital Status | |||||||
Yes | 1086 | 62.09% | 746 | 62.85% | 340 | 60.50% | 0.3443 |
No | 663 | 37.91% | 441 | 37.15% | 222 | 39.50% |